123 related articles for article (PubMed ID: 38155749)
1. The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF-κB Pathway in Non-Small Cell Lung Cancer [Retraction].
Onco Targets Ther; 2023; 16():1073-1074. PubMed ID: 38155749
[TBL] [Abstract][Full Text] [Related]
2. The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF-κB Pathway in Non-Small Cell Lung Cancer.
Chen Y; Lei Y; Lin J; Huang Y; Zhang J; Chen K; Sun S; Lin X
Onco Targets Ther; 2020; 13():10707-10719. PubMed ID: 33116647
[TBL] [Abstract][Full Text] [Related]
3. Long Non-Coding RNA LINC01260 Inhibits the Proliferation, Migration and Invasion of Spinal Cord Glioma Cells by Targeting CARD11 Via the NF-κB Signaling Pathway.
Wu DM; Han XR; Wen X; Wang S; Wang YJ; Shen M; Fan SH; Zhuang J; Zhang ZF; Shan Q; Li MQ; Hu B; Sun CH; Lu J; Zheng YL
Cell Physiol Biochem; 2018; 48(4):1563-1578. PubMed ID: 30071522
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of isosteviol sodium through increasing CYLD by the downregulation of miRNA-181b.
Zhang H; Zhong K; Lu M; Mei Y; Tan E; Sun X; Tan W
Brain Res Bull; 2018 Jun; 140():392-401. PubMed ID: 29807144
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling.
Xia JT; Chen LZ; Jian WH; Wang KB; Yang YZ; He WL; He YL; Chen D; Li W
J Transl Med; 2014 Feb; 12():33. PubMed ID: 24495516
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the CYLD/Nf-κB axis to promote breast cancer progression.
Ren Z; Lv M; Yu Q; Bao J; Lou K; Li X
FASEB J; 2021 Mar; 35(3):e21383. PubMed ID: 33629796
[TBL] [Abstract][Full Text] [Related]
7. Long Noncoding RNA NEAT1 Promotes Nasopharyngeal Carcinoma Progression Through Regulation of miR-124/NF-κB Pathway [Retraction].
Onco Targets Ther; 2023; 16():639-640. PubMed ID: 37525845
[TBL] [Abstract][Full Text] [Related]
8. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells.
Takiuchi D; Eguchi H; Nagano H; Iwagami Y; Tomimaru Y; Wada H; Kawamoto K; Kobayashi S; Marubashi S; Tanemura M; Mori M; Doki Y
Pancreatology; 2013; 13(5):517-23. PubMed ID: 24075517
[TBL] [Abstract][Full Text] [Related]
9. miR-765 Acts as a Tumor Promoter and Indicates Poor Prognosis in Non-Small Cell Lung Cancer [Retraction].
Onco Targets Ther; 2023; 16():937-938. PubMed ID: 38021443
[TBL] [Abstract][Full Text] [Related]
10. PVT1 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer via Regulating miR-148/RAB34 Signal Axis [Retraction].
Onco Targets Ther; 2023; 16():653-654. PubMed ID: 37551310
[TBL] [Abstract][Full Text] [Related]
11. The lncRNA LINC01194/miR-486-5p Axis Facilitates Malignancy in Non-Small Cell Lung Cancer via Regulating CDK4 [Retraction].
Onco Targets Ther; 2024; 17():147-148. PubMed ID: 38420288
[TBL] [Abstract][Full Text] [Related]
12. Hsa_circ_RNA_0011780 Represses the Proliferation and Metastasis of Non-Small Cell Lung Cancer by Decreasing FBXW7 via Targeting miR-544a [Retraction].
Onco Targets Ther; 2022; 15():1385-1386. PubMed ID: 36419866
[TBL] [Abstract][Full Text] [Related]
13. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA Sox2 Overlapping Transcript (SOX2OT) Promotes Non-Small-Cell Lung Cancer Migration and Invasion via Sponging microRNA 132 (miR-132) [Retraction].
Onco Targets Ther; 2021; 14():5003-5004. PubMed ID: 34675544
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional downregulation of microRNA-19a by ROS production and NF-κB deactivation governs resistance to oxidative stress-initiated apoptosis.
Hong J; Wang Y; Hu BC; Xu L; Liu JQ; Chen MH; Wang JZ; Han F; Zheng Y; Chen X; Li Q; Yang XH; Sun RH; Mo SJ
Oncotarget; 2017 Sep; 8(41):70967-70981. PubMed ID: 29050336
[TBL] [Abstract][Full Text] [Related]
16. Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.
Byun JY; Yune TY; Lee JY; Yeo SG; Park MS
Mediators Inflamm; 2010; 2010():796315. PubMed ID: 20414373
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
18. MiR-29a Function as Tumor Suppressor in Cervical Cancer by Targeting SIRT1 and Predict Patient Prognosis [Retraction].
Onco Targets Ther; 2023; 16():749-750. PubMed ID: 37727440
[TBL] [Abstract][Full Text] [Related]
19. Expanding CYLD protein in NF-κβ/TNF-α signaling pathway in response to Lactobacillus acidophilus in non-metastatic rectal cancer patients.
Zamani F; Khalighfard S; Kalhori MR; Poorkhani A; Amiriani T; Hosseinzadeh P; Esmati E; Alemrajabi M; Nikoofar A; Safarnezhad Tameshkel F; Alizadeh AM
Med Oncol; 2023 Sep; 40(10):302. PubMed ID: 37725175
[TBL] [Abstract][Full Text] [Related]
20. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells.
Deng LL; Shao YX; Lv HF; Deng HB; Lv FZ
Neoplasma; 2012; 59(1):18-29. PubMed ID: 22017589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
